In Phase C, individuals will get ABBV-744 and oral navitoclax. In Section D, individuals will obtain ABBV-744 and ruxolitinib. Individuals will receive treatment until eventually illness progression or even the participants are unable to tolerate the study drugs. - "Our study unveiled the essential job in the KLF16/MYC regulatory axis https://isabbv-744effectiveforhem46801.blogdomago.com/31126324/not-known-factual-statements-about-abbv-744-preclinical-studies-and-results